|
Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis Clinical research trials and Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis. Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis clinical trial. Subjects frequently get the best healthcare possible for their Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis  Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis
Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis
For Condition: Histoplasmosis,Blastomycosis,Sporotrichosis
Status: Completed
Sponsor(s): National Center for Research Resources (NCRR) , National Institute of Allergy and Infectious Diseases (NIAID),University of Alabama
Synopsis: OBJECTIVES: I. Identify a preferred oral fluconazole dose regimen for patients with non-acute histoplasmosis or blastomycosis, or ulcerocutaneous or deep sporotrichosis. II. Study the safety and efficacy of fluconazole in these patients.
Details: PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by participating institution and type of infection. Patients with blastomycosis are randomly assigned to moderate- versus high-dose oral fluconazole. Based on clinical response, the dose is increased at 1 and 2 months for patients in the moderate-dose group. Patients in the high-dose group receive a fixed dose of fluconazole. Patients with histoplasmosis and sporotrichosis are nonrandomly treated with moderate-dose fluconazole. Therapy is administered daily for 3 months beyond stabilization of infection (maximum 24 months), or for a total of 6 months if the infection stabilizes within 3 months. Fluconazole may be administered intravenously (maximum 7 days) if the oral dose is not tolerated. Concurrent systemic or intrathecal antifungals, immunostimulants, and lymphocyte replacement are prohibited. Investigational agents or approved agents given for investigational indications are also not permitted on study. Patients are followed at 3, 6, and 12 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 12 Years/
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Clinical, radiographic, nuclear medicine, or similar study findings compatible with active infection with any of the following: Histoplasma capsulatum Blastomyces dermatiditis Sporothrix schenckii - At least 1 positive culture within 8 weeks prior to entry Diagnostic histopathology fulfills requirement if confirmed by second independent reviewer - Sporotrichosis, i.e.: Ulcerocutaneous disease limited to local or regional skin and lymphatics OR Deep infection of tissue or sites other than locoregional skin/lymphatics - Histoplasmosis and blastomycosis with acute pulmonary infection as sole site of disease eligible only if progressive, i.e.: Clinically or radiographically apparent new lesions or continued increase in old lesions for more than 20 days after acute illness onset Positive culture or histopathology at least 20 days after illness onset - Relapsed disease eligible, as follows: Clinical evidence of active disease Positive culture within 8 weeks prior to entry Histopathologic evidence alone not acceptable for entry No more than 3 days of systemic amphotericin B or ketoconazole since positive culture - Infection site present at study entry, i.e., no prior surgical removal - No active meningeal or central nervous system infection Diagnostic tests required if symptomatic - No immediately life-threatening infection --Patient Characteristics-- - Life expectancy: At least 1 week - Hepatic: AST and ALT no greater than 5 times normal Alkaline phosphatase no greater than 5 times normal Bilirubin no greater than 5 times normal PT no greater than 5 seconds above normal or control and not corrected with vitamin K - Other: No HIV infection No AIDS (Centers for Disease Control and Prevention criteria) No requirement for any of the following: Barbiturates Phenytoin Oral hypoglycemics Coumarin-type anticoagulants No pregnant or nursing women Negative pregnancy test required of fertile women Effective contraception required of fertile women
Total Enrollment: 78
Location and Contact Information:
Overall Study Official:
WilliamDismukes, Study Chair, University of Alabama
Additional Information:
Study ID Numbers: 199/12010; NIAID-MSG-13
Study Start Date: September 1991
Record last reviewed: December 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004808
Other Histoplasmosis Studies:
1. Submacular Surgery Trials (SST)
2. Withdrawal of Antifungal Treatment for Histoplasmosis in Patients after Improved Immune Response to Anti-HIV Drugs
3. Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients with the Acquired Immunodeficiency Syndrome
4. A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis
5. Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis
Related Studies:
Other Histoplasmosis Clinical Trials
Other Clinical Trials
Other Clinical Trials
Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis
|
|
|
|
|
|
|
|
